New drugs in acute myelogenous leukemia: a review.
Numerous clinical trials in adult patients with newly diagnosed acute myelogenous leukemia indicate that the survival rate is approximately 20%. A limited number of favorable prognostic features have been identified; patients who present with specific cytogenetic abnormalities such as t(15;17), t(8;21) and inv (16) tend to have survival rates approaching 40%. However, such patients constitute only a small proportion of the total denominator and it has therefore been a major focus of scientific endeavor to develop new drugs for the treatment of this disease. A wide variety of agents have undergone preliminary testing in this regard and include both natural substances such as homoherringtonine, a drug that has demonstrated modest complete remission rates in this disease and all-trans retinoic acid, a compound that has revolutionized the treatment of acute promyelocytic leukemia. This review will put in perspective some of the newer drugs for the treatment of acute myelogenous leukemia and allow for some conclusions to be drawn as to their impact in the treatment of this disease.
Berman
E
E
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
D000677:Amsacrine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D007536:Isomerism; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008942:Mitoxantrone / Q000627:therapeutic use; D012074:Remission Induction; D015996:Survival Rate; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000677:Amsacrine; D003561:Cytarabine; D014212:Tretinoin; D008942:Mitoxantrone; D015255:Idarubicin; D003630:Daunorubicin